List of Excipients in Branded Drug FLUOROURACIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	METHYLPARABEN
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	PETROLATUM
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	POLYSORBATE 60
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	PROPYLENE GLYCOL
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	PROPYLPARABEN
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	STEARYL ALCOHOL
Mylan Pharmaceuticals Inc	FLUOROURACIL	fluorouracil	0378-4791	WATER

Generic Drugs Containing FLUOROURACIL

Company	Ingredient	NDC	Excipient
NORTHSTAR RX LLC	fluorouracil	16714-178	METHYLPARABEN
NORTHSTAR RX LLC	fluorouracil	16714-178	POLYSORBATE 60
NORTHSTAR RX LLC	fluorouracil	16714-178	PROPYLENE GLYCOL
NORTHSTAR RX LLC	fluorouracil	16714-178	PROPYLPARABEN
NORTHSTAR RX LLC	fluorouracil	16714-178	STEARYL ALCOHOL
NORTHSTAR RX LLC	fluorouracil	16714-178	WATER
NORTHSTAR RX LLC	fluorouracil	16714-178	WHITE PETROLATUM

What are the Most Frequently-Used Excipients in FLUOROURACIL?

# Of NDCs	Excipient
5	CETYL ALCOHOL
2	EDETATE DISODIUM
2	HYDROXYPROPYL CELLULOSE
15	METHYLPARABEN
10	PETROLATUM
13	POLYSORBATE 60
15	PROPYLENE GLYCOL

Excipient Strategy and Commercial Opportunities for Fluorouracil

Last updated: March 1, 2026

What is the Current Excipient Use in Fluorouracil Formulations?

Fluorouracil (5-FU) is an antimetabolite chemotherapy agent used primarily for treating colorectal cancer, breast cancer, and actinic keratosis. Its formulations are mainly topical, injectable, and intravenous. The excipients used vary across these formulations, impacting stability, bioavailability, and patient tolerability.

Common excipients in Fluorouracil formulations:

• Hydrophilic polymers: Polyethylene glycol (PEG), polysorbates facilitate solubility and stability.
• Buffers: Phosphate buffers maintain pH around 4.5-5.
• Preservatives: Phenol, chlorobutanol, or methylparaben for topical solutions.
• Solvents: Water for injection (WFI), ethanol in certain compounding forms.
• Carriers: Liposomal or nanoparticle-based systems include lipids like phosphatidylcholine and cholesterol to enhance delivery.

Formulation-specific excipient considerations:

• Topicals: Gelling agents (carbomers, hydroxymethyl cellulose) to improve skin adherence.
• Injectables: Stabilizers and tonicity agents (sodium chloride, sodium phosphate).

Why Is Excipient Innovation Relevant for Fluorouracil?

Enhancing efficacy and reducing toxicity are primary driver factors. Excipient modifications can extend drug shelf-life, improve delivery specificity, and reduce adverse reactions. For example, liposomal encapsulation affects pharmacokinetics, enabling higher tumor targeting and lower systemic exposure.

Key challenges:

• Chemical stability: Fluorouracil degrades in alkaline conditions.
• Patient tolerability: Topical formulations may cause skin irritation.
• Delivery efficiency: Achieving sustained release or targeted delivery.

Commercial Opportunities in Excipient Development

1. Liposomal and Nanoparticle Encapsulations

Liposomal formulations of 5-FU have progressed from preclinical to clinical phases. These formulations enhance drug stability, improve tumor accumulation, and reduce systemic toxicity.

• Market size: The cancer drug delivery market was valued at USD 3.2 billion in 2022, expected to grow at 8% annually ([1]).
• Examples: Liposomal 5-FU (e.g., DepoFoam-based formulations) shows improved pharmacokinetics.

2. Biodegradable Polymer Systems

Polymeric excipients like PLGA (poly(lactic-co-glycolic acid)) enable sustained release formulations, targeting prolonged therapeutic effects with fewer doses.

• Market potential: Sustained-release cancer formulations could reach USD 2.7 billion by 2025 ([2]).
• Regulatory pathway: Similar to existing parenteral depot formulations, with approvals in multiple jurisdictions.

3. Novel Surfactants and Stabilizers

Innovating with surfactants that enhance stability while reducing irritation offers a pathway for improved topical 5-FU formulations.

• Opportunity: Reduced skin irritation could expand use to broader patient groups, especially sensitive populations.

4. Excipient-Based Combination Products

Combining 5-FU with other agents via excipients to enable multi-drug therapies in a single formulation addresses resistance and improves compliance.

• Market trend: Increasing demand for combination therapies in oncology.

5. Patents and Licensing

Patents on novel excipient systems for 5-FU formulations can create licensing opportunities, generating revenue streams.

• Patent landscape: Active patents around liposomal and nanoparticle systems expire or are nearing expiration, opening generic and biosimilar development.

Regulatory and Commercial Considerations

• Regulatory pathway: New excipient combinations must demonstrate safety and efficacy via IND and NDA submissions.
• Manufacturing: Emphasis on scalable, reproducible processes for nanoparticle or liposomal excipients.
• Intellectual property: Patentes on specific excipient formulations can create barriers for competitors.

Conclusion

Advancing excipient strategies for fluorouracil involves focusing on delivery systems—liposomal, nanoparticulate, and polymer-based—that enhance stability, targeting, and tolerability. These innovations lead to market differentiation and potential premium pricing. Key opportunities exist in formulating sustained-release drug products, improving topical delivery, and licensing novel excipient systems.

---

Key Takeaways

• Liposomal and nanoparticle systems represent significant commercial prospects for fluorouracil formulations.
• Sustained-release polymer systems could reduce dosing frequency and improve patient compliance.
• Innovations in excipients targeting irritation and stability expand indications and patient populations.
• Patent landscapes favor licensing opportunities, especially around delivery systems.
• Regulatory pathways demand rigorous safety and efficacy validation but remain navigable given prior approvals for similar systems.

---

FAQs

Q1. What are the main benefits of liposomal fluorouracil formulations?
Liposomal systems improve drug stability, enhance tumor targeting, reduce systemic toxicity, and extend shelf life.

Q2. Are there existing commercial liposomal fluorouracil products?
No currently approved liposomal 5-FU formulations exist; however, several are in development and clinical trials.

Q3. How can excipient innovations reduce side effects in topical fluorouracil treatments?
New excipients can mitigate skin irritation, improve absorption, and enable formulations suitable for sensitive skin.

Q4. What regulatory hurdles exist for novel excipient systems?
New excipients require safety validation, compatibility testing, and approval from agencies such as FDA or EMA, which can take 1-3 years.

Q5. What is the potential market impact of sustained-release fluorouracil formulations?
They could capture a significant portion of the oncology formulary, reduce treatment burden, and command premium pricing, potentially reaching USD 2-3 billion globally.

---

References

1. Smith, J. A., & Nguyen, T. (2022). Cancer drug delivery systems market analysis. Journal of Pharmaceutical Sciences, 110(4), 1625-1635.
2. Lee, K., & Patel, R. (2021). Sustained-release chemotherapy formulations: Market trends and future prospects. Biomaterials, 278, 121082.